López-Ibor J J, Saiz J, Cottraux J, Note I, Viñas R, Bourgeois M, Hernández M, Gómez-Pérez J C
Hospital Universitario San Carlos, Madrid, Spain.
Eur Neuropsychopharmacol. 1996 May;6(2):111-8. doi: 10.1016/0924-977x(95)00071-v.
There is evidence of the clinical efficacy and safety of clomipramine and the newer selective serotonin reuptake inhibitors (SSRIs) for the treatment of obsessive-compulsive disorder (OCD). In the present study, we have compared the efficacy and safety of 40 mg/day of fluoxetine and 150 mg/day of clomipramine in patients with OCD, diagnosed according to DSM-IIIR. A total of 55 patients entered this 8-week, double-blind controlled study. Efficacy for both drugs was comparable. The primary efficacy criterion, the Y-BOCS Total score, did not show any significant differences between treatment arms. Response rate was higher with clomipramine, using a 25% decrease in Y-BOCS Total score as response threshold, but there were no significant differences between treatment arms using a 35% threshold. Overall safety and tolerability were good for both drugs, being slightly better for fluoxetine.
有证据表明氯米帕明及更新的选择性5-羟色胺再摄取抑制剂（SSRI）对治疗强迫症（OCD）具有临床疗效和安全性。在本研究中，我们比较了每日40毫克氟西汀和每日150毫克氯米帕明对根据《精神疾病诊断与统计手册》第三版修订本（DSM-IIIR）诊断的强迫症患者的疗效和安全性。共有55名患者进入了这项为期8周的双盲对照研究。两种药物的疗效相当。主要疗效标准，即耶鲁布朗强迫症量表（Y-BOCS）总分，在各治疗组之间未显示出任何显著差异。以Y-BOCS总分降低25%作为反应阈值时，氯米帕明的反应率更高，但以35%为阈值时，各治疗组之间无显著差异。两种药物的总体安全性和耐受性都良好，氟西汀的安全性和耐受性略好。
Zotero 插件